DE69812933D1 - FARNESYL TRANSFERASEINHIBITOREN IN KOMBINATION MIT HMG CoA REDUKTASEINHIBITOR UND DEREN VERWENDUNG IN DER KREBSTHERAPIE - Google Patents

FARNESYL TRANSFERASEINHIBITOREN IN KOMBINATION MIT HMG CoA REDUKTASEINHIBITOR UND DEREN VERWENDUNG IN DER KREBSTHERAPIE

Info

Publication number
DE69812933D1
DE69812933D1 DE69812933T DE69812933T DE69812933D1 DE 69812933 D1 DE69812933 D1 DE 69812933D1 DE 69812933 T DE69812933 T DE 69812933T DE 69812933 T DE69812933 T DE 69812933T DE 69812933 D1 DE69812933 D1 DE 69812933D1
Authority
DE
Germany
Prior art keywords
inhibitors
combination
cancer therapy
hmg coa
transferas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69812933T
Other languages
English (en)
Other versions
DE69812933T2 (de
Inventor
Mohammed Kajiji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE69812933D1 publication Critical patent/DE69812933D1/de
Publication of DE69812933T2 publication Critical patent/DE69812933T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69812933T 1997-06-16 1998-06-05 FARNESYL TRANSFERASEINHIBITOREN IN KOMBINATION MIT HMG CoA REDUKTASEINHIBITOR UND DEREN VERWENDUNG IN DER KREBSTHERAPIE Expired - Fee Related DE69812933T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16
PCT/IB1998/000881 WO1998057633A1 (en) 1997-06-16 1998-06-05 FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER

Publications (2)

Publication Number Publication Date
DE69812933D1 true DE69812933D1 (de) 2003-05-08
DE69812933T2 DE69812933T2 (de) 2003-11-06

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69812933T Expired - Fee Related DE69812933T2 (de) 1997-06-16 1998-06-05 FARNESYL TRANSFERASEINHIBITOREN IN KOMBINATION MIT HMG CoA REDUKTASEINHIBITOR UND DEREN VERWENDUNG IN DER KREBSTHERAPIE

Country Status (37)

Country Link
EP (1) EP0986387B1 (de)
JP (1) JP3713051B2 (de)
KR (1) KR100392573B1 (de)
CN (1) CN1259868A (de)
AP (1) AP9801261A0 (de)
AR (1) AR013090A1 (de)
AT (1) ATE235905T1 (de)
BG (1) BG103946A (de)
BR (1) BR9810616A (de)
CA (1) CA2294399C (de)
CO (1) CO4950607A1 (de)
DE (1) DE69812933T2 (de)
DK (1) DK0986387T3 (de)
DZ (1) DZ2518A1 (de)
EA (1) EA199901043A1 (de)
ES (1) ES2196559T3 (de)
GT (1) GT199800081A (de)
HN (1) HN1998000091A (de)
HR (1) HRP980328B1 (de)
HU (1) HUP0004624A3 (de)
ID (1) ID23014A (de)
IL (1) IL132765A0 (de)
IS (1) IS5259A (de)
MA (1) MA24569A1 (de)
NO (1) NO996206L (de)
NZ (1) NZ500662A (de)
OA (1) OA11231A (de)
PA (1) PA8453601A1 (de)
PE (1) PE82899A1 (de)
PL (1) PL337651A1 (de)
PT (1) PT986387E (de)
SK (1) SK169699A3 (de)
TN (1) TNSN98088A1 (de)
TR (1) TR199903074T2 (de)
UA (1) UA57081C2 (de)
WO (1) WO1998057633A1 (de)
ZA (1) ZA985182B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27933A (id) 1998-05-12 2001-05-03 Warner Lambert Co Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker
WO2000016778A1 (en) * 1998-09-24 2000-03-30 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (de) 1998-12-02 2000-06-07 Pfizer Products Inc. 2-(2-oxo-ethyliden)-imidazolidin-4-one-Derivate und ihre Verwendung zur Inhibierung des abnormalen Zellwachstums
WO2000067737A2 (en) * 1999-05-07 2000-11-16 The Brigham And Women's Hospital, Inc. USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
JP2004516287A (ja) 2000-12-19 2004-06-03 ファイザー・プロダクツ・インク 6−[(4−クロロ−フェニル)−ヒドロキシ−(3−メチル−3h−イミダゾール−4−イル)−メチル]−4−(3−エチニル−フェニル)−1−メチル−1h−キノリン−2−オン,2,3−ジヒドロキシブタン二酸塩の結晶形および製造方法
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド,インク. 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005902A1 (fr) * 1995-08-09 1997-02-20 Banyu Pharmaceutical Co., Ltd. Composition medicinale

Also Published As

Publication number Publication date
CO4950607A1 (es) 2000-09-01
ES2196559T3 (es) 2003-12-16
IL132765A0 (en) 2001-03-19
NZ500662A (en) 2001-10-26
PT986387E (pt) 2003-06-30
OA11231A (en) 2003-05-26
TNSN98088A1 (fr) 2005-03-15
GT199800081A (es) 1999-12-07
AU7445998A (en) 1999-01-04
HUP0004624A3 (en) 2002-11-28
ID23014A (id) 1999-12-30
PA8453601A1 (es) 2000-05-24
SK169699A3 (en) 2000-06-12
CA2294399C (en) 2004-03-16
ATE235905T1 (de) 2003-04-15
MA24569A1 (fr) 1998-12-31
UA57081C2 (uk) 2003-06-16
HRP980328A2 (en) 1999-04-30
IS5259A (is) 1999-11-19
EP0986387B1 (de) 2003-04-02
DZ2518A1 (fr) 2003-02-01
NO996206L (no) 2000-02-15
CN1259868A (zh) 2000-07-12
NO996206D0 (no) 1999-12-15
JP2000513031A (ja) 2000-10-03
HN1998000091A (es) 1999-09-29
DE69812933T2 (de) 2003-11-06
DK0986387T3 (da) 2003-07-14
JP3713051B2 (ja) 2005-11-02
BR9810616A (pt) 2000-09-12
BG103946A (bg) 2000-07-31
KR20010013839A (ko) 2001-02-26
AP9801261A0 (en) 1999-12-11
EP0986387A1 (de) 2000-03-22
PL337651A1 (en) 2000-08-28
WO1998057633A1 (en) 1998-12-23
EA199901043A1 (ru) 2000-06-26
HRP980328B1 (en) 2002-06-30
CA2294399A1 (en) 1998-12-23
HUP0004624A2 (hu) 2001-10-28
AR013090A1 (es) 2000-12-13
TR199903074T2 (xx) 2000-05-22
KR100392573B1 (ko) 2003-07-23
PE82899A1 (es) 1999-08-26
ZA985182B (en) 1999-12-17
AU724676B2 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
DE69736994D1 (de) Ionische Malonsäuredinitril Derivate und deren Verwendung
DE69927289D1 (de) Hochfeste epoxidharzklebstoffe und deren verwendung
NO982913D0 (no) Kinolin- og kinazolinforbindelser nyttige i terapi
DE69826007D1 (de) Tetrafluorethylencopolymer und dessen verwendung
FI951801A (fi) CTLA4-molekyylit ja IL4:sitovat molekyylit sekä näiden käyttö
DE69622148T2 (de) Chinazozin derivate und deren verwendung
DE69806925T2 (de) Ligand-aminodextran-markierungsubstanzkonjugate und deren verwendung
DE59604168D1 (de) Alkalifreies Aluminoborosilicatglas und dessen Verwendung
DE69821400D1 (de) Basismaterial und mit einem solchen Klebeband
DE59810824D1 (de) Optik-Fassung mit UV-Kleber und Schutzschicht
DE69817432D1 (de) Cycloolefinpolymere und deren Verwendung
DE69515809D1 (de) Fahrgestell mit verstellbarer Spurbreite
DE69915066D1 (de) Biozide zusammensetzung und deren verwendung
DE69812933D1 (de) FARNESYL TRANSFERASEINHIBITOREN IN KOMBINATION MIT HMG CoA REDUKTASEINHIBITOR UND DEREN VERWENDUNG IN DER KREBSTHERAPIE
DE59301428D1 (de) Polymerharze und deren Verwendung
DE69835007D1 (de) Entkoffeinierte mate-extrakte und deren verwendung
DE69720946T2 (de) Spitzenwertdetektor und dessen verwendung
EE200000660A (et) Valk farnesüültransferaasi ja HMG CoA reduktaasi inhibiitorite kombinatsioonid ja nende kasutamine vähi raviks
DE59508820D1 (de) Elektrolumineszierende Anordnungen und deren Verwendung
DE69529629T2 (de) Konjugierte N-Fluorpyridinum Salzpolymere und deren Verwendung
DE69812256D1 (de) 7-propyl-benzodiosepin-3-one und dessen Verwendung in Parfümerie
DE69521174T2 (de) Anthrachinonderivate mit antitumorwirkung und ihre verwendung
DE69900802T2 (de) MnMgCuZn-Ferrit und dessen Verwendung
DE59407017D1 (de) Strahlungsanordnung mit reflektorkörper und deren verwendung
DE69420933T2 (de) Salzzusammensetzungen und deren Verwendung in funktionellen Flüssigkeiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee